Relieving Distress in Parents Caring for a Child Undergoing a Hematopoietic Stem Cell Transplant

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2010 by National Cancer Institute (NCI).
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00953082
First received: August 5, 2009
Last updated: April 6, 2010
Last verified: April 2010
  Purpose

RATIONALE: A program that helps parents learn to cope with the distress of caring for a child undergoing stem cell transplant may reduce depression and anxiety and improve the well-being of the parent.

PURPOSE: This randomized clinical trial is studying ways to relieve distress in parents caring for a child undergoing transplant.


Condition Intervention
Psychosocial Effects of Cancer and Its Treatment
Other: computer-assisted intervention
Other: medical chart review
Other: psychosocial support for caregiver
Other: questionnaire administration
Other: study of socioeconomic and demographic variables
Procedure: assessment of therapy complications
Procedure: psychosocial assessment and care

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Single Blind
Official Title: Facilitating Parent Adaptation to Pediatric Transplant: The P-SCIP Trial

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Depressive symptoms, anxiety, general well-being of parent [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Parent social and cognitive processing [ Designated as safety issue: No ]
  • Barriers to participation in the intervention trial [ Designated as safety issue: No ]

Estimated Enrollment: 312
Study Start Date: January 2008
Estimated Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

Primary

  • To evaluate the relative impact of the Parent Social-Cognitive Intervention Program (P-SCIP) vs the Best-Recommended Psychosocial Care (BPC) interventions on parent short- and long-term psychological distress.
  • To evaluate parent personal resources as well as child medical course variables that contribute to intervention response.

Secondary

  • To examine differential effects of P-SCIP vs BPC on parent social and cognitive processing.
  • To investigate barriers to participation in the intervention trial.

OUTLINE: This is a multicenter study.

Participants are stratified according to caregiving parent status (father vs mother), study center, and primary parent caregiver language at CHLA vs Columbia (English vs Spanish). Participants are randomized to 1 of 2 intervention arms.

  • Arm I (Parent Social-Cognitive Intervention Program [P-SCIP]): Participants undergo five 60-minute behavioral intervention sessions once or twice weekly for 3 weeks to learn how to engage in effective social and cognitive processing to deal with fears and worries about the transplant and transplant-related concerns. Participants receive a laptop computer and a CD-ROM after the first session.
  • Arm II (Best-recommended Psychosocial Care [BPC]): Participants undergo usual care and receive a "Discovery to Recovery" DVD and pamphlet developed by the National Marrow Donor Program (NMDP) describing psychological issues associated with hematopoietic stem cell transplantation (HSCT), the booklet "Top Tips for Parent Caregivers During the BMT Process" published by National Marrow Donor Program-Link describing caregiver issues during HSCT and advice on how to handle them, 2 walkie-talkies, a laptop to view the DVD, and 5 hours of respite care from a child-life specialist once or twice weekly for 3 weeks.

Participants are assessed periodically by demographic information, hospitalization for emotional problems, psychosocial services (i.e., religious counseling, professional counseling, attending a support or therapy group, and other support services in the past month), psychosocial care services during the child's HSCT hospitalization, psychotropic medications and sleep medications taken, optimism by the Life Orientation Test, enacted social support, informational support from medical team, treatment Expectancy, Working Alliance Inventory, homework adherence (P-SCIP only), utilization of the CD-ROM/DVD, use of offer of respite care by Child Life Specialist (BPC only), psychosocial and supportive care available at site, and mental health services by the Awareness and Barriers to Counseling-Revised questionnaire.

After completion of study intervention, participants are followed up at 1, 6, and 12 months.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

DISEASE CHARACTERISTICS:

  • Biological or foster parent of child < 18 years of age scheduled for hematopoietic stem cell transplantation (HSCT) within the next month

    • Child must not have medulloblastoma or other brain cancer
  • Primary caregiver, defined as the parent who self-identifies as intending to play a primary caregiving role, to the child during HSCT

PATIENT CHARACTERISTICS:

  • Has residential phone service
  • Speaks English or Spanish

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00953082

Locations
United States, California
Childrens Hospital Los Angeles Recruiting
Los Angeles, California, United States, 90027
Contact: Ernest Katz, PhD     323-669-2516        
United States, Georgia
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus Recruiting
Atlanta, Georgia, United States, 30322
Contact: Laura L. Mee, PhD     404-785-1241        
United States, New York
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center Recruiting
New York, New York, United States, 10032
Contact: Clinical Trials Office - Herbert Irving Comprehensive Cancer C     212-305-8615        
Memorial Sloan-Kettering Cancer Center Recruiting
New York, New York, United States, 10065
Contact: Abraham Bartell, MD, MBA     646-888-0023        
United States, Pennsylvania
Fox Chase Cancer Center - Philadelphia Recruiting
Philadelphia, Pennsylvania, United States, 19111-2497
Contact: Clinical Trials Office - Fox Chase Cancer Center - Philadelphi     215-728-4790        
Sponsors and Collaborators
Fox Chase Cancer Center
Investigators
Principal Investigator: Sharon Manne, PhD Fox Chase Cancer Center
  More Information

Additional Information:
No publications provided

Responsible Party: Sharon Manne, Fox Chase Cancer Center - Philadelphia
ClinicalTrials.gov Identifier: NCT00953082     History of Changes
Other Study ID Numbers: CDR0000632012, FCCC-07848
Study First Received: August 5, 2009
Last Updated: April 6, 2010
Health Authority: Unspecified

Keywords provided by National Cancer Institute (NCI):
psychosocial effects of cancer and its treatment

ClinicalTrials.gov processed this record on May 16, 2013